Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer

Manjula Darshi, Benjamin Van Espen, Kumar Sharma

Producción científica: Review articlerevisión exhaustiva

65 Citas (Scopus)


The development of new therapies for chronic diseases, such as diabetic kidney disease (DKD), will continue to be hampered by lack of sufficient biomarkers that will provide insights and will be responsive to treatment interventions. The recent application of metabolomic technologies, such as nuclear magnetic resonance and mass spectroscopy, has allowed large-scale analysis of small molecules to be interrogated in a targeted or untargeted manner. Recent advances from both human and animal studies that have arisen from metabolomic analysis have recognized that mitochondrial function and fatty acid oxidation play key roles in the development and progression of DKD. Although many challenges in the technology for clinical chronic kidney disease (CKD) are yet to be validated, there will very likely be ongoing major contributions of metabolomics to develop new biochemical understanding for diabetic and CKD. The clinical application of metabolomics and accompanying bioinformatic tools will likely be a cornerstone of personalized medicine triumphs for CKD.

Idioma originalEnglish (US)
Páginas (desde-hasta)92-103
Número de páginas12
PublicaciónAmerican journal of nephrology
EstadoPublished - sept 1 2016
Publicado de forma externa

ASJC Scopus subject areas

  • Nephrology


Profundice en los temas de investigación de 'Metabolomics in Diabetic Kidney Disease: Unraveling the Biochemistry of a Silent Killer'. En conjunto forman una huella única.

Citar esto